{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:19:46Z","timestamp":1794431986703,"version":"4.9.1"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019719","name":"Chiesi Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019719","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In patients with Fabry disease (FD), treatment with enzyme replacement therapy (ERT), may trigger the formation of anti-drug antibodies (ADAs). The consequences of this immune reaction range from the transient appearance of clinically insignificant ADAs to the generation of neutralizing antibodies that negate the clinical benefit of the biotherapeutic agent, lead to side effects (such as injection site reactions), and even cause severe, life-threatening symptoms. Many factors may influence the immunogenicity of these therapeutic proteins. Currently, there are three commercially available long-term ERT treatments in patients with FD: agalsidase alfa, agalsidase beta, and more recently, pegunigalsidase alfa. Neutralizing ADAs are present in approximately 40% of male FD patients treated with ERT based on agalsidase alfa or agalsidase beta and have shown in vitro cross-reactivity with both agalsidases. Their formation seems to be irreversible, meaning that most patients with positive neutralizing ADAs remain so for up to 10\u00a0years after starting treatment. Recent studies show that in some patients, pre-existing ADAs against agalsidase alfa and agalsidase beta have lower affinity and lower inhibitory effects against pegunigalsidase alfa. Additionally, in clinical trials involving na\u00efve patients, neutralizing antibodies were mostly transient, although further studies are needed to confirm these findings in clinical practice. The formation of ADAs is often associated with a worse clinical prognosis and a faster progression of the disease. Given the rapid progression of FD, measuring ADAs titers is essential to provide personalised treatment for each patient. This is why international recommendations highlight the importance of monitoring the existence of ADAs, their neutralising activity, and globotriaosylsphingosine (lyso-Gb3) levels in patients receiving ERT. However, several unresolved issues remain, such as the importance of ADAs levels (particularly neutralising ADAs), the standardisation of assay methods, the interpretation of results, and the implications of these findings for therapeutic strategies. Overcoming the development of ADAs is critical to improving treatment outcomes in patients with FD, different strategies have been explored to address this challenge. The present work aims to review latest developments related to all aspects mentioned above, while also analyzing the potential role of therapeutic innovations.<\/jats:p>","DOI":"10.1186\/s13023-025-03705-4","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T13:43:29Z","timestamp":1748267009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Current status of the immunogenicity of enzyme replacement therapy in fabry disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Jorge F.","family":"G\u00f3mez-Cerezo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Fern\u00e1ndez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Barba-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"S\u00e1nchez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Hermida-Ameijeiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2359-3238","authenticated-orcid":false,"given":"Maria","family":"Camprodon-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saida","family":"Ortolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica A.","family":"Lopez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"3705_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-30","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010. https:\/\/doi.org\/10.1186\/1750-1172-5-30.","journal-title":"Orphanet J Rare Dis."},{"issue":"4","key":"3705_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138(4):338\u201346.","journal-title":"Ann Intern Med"},{"issue":"3","key":"3705_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2174\/1570159X20666220601124117","volume":"21","author":"L Palaiodimou","year":"2023","unstructured":"Palaiodimou L, Kokotis P, Zompola C, Papagiannopoulou G, Bakola E, Papadopoulou M, et al. Fabry disease: current and novel therapeutic strategies. A Narrative Review Curr Neuropharmacol. 2023;21(3):440\u201356.","journal-title":"A Narrative Review Curr Neuropharmacol"},{"key":"3705_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02937-6","author":"A Linhart","year":"2023","unstructured":"Linhart A, Dost\u00e1lov\u00e1 G, Nicholls K, West ML, T\u00f8ndel C, Jovanovic A, et al. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. Orphanet J Rare Dis. 2023. https:\/\/doi.org\/10.1186\/s13023-023-02937-6.","journal-title":"Orphanet J Rare Dis."},{"key":"3705_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/B978-0-444-62702-5.00017-2","volume":"132","author":"R Schiffmann","year":"2015","unstructured":"Schiffmann R. Fabry disease. Handb Clin Neurol. 2015;132:231\u201348.","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"3705_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416\u201327.","journal-title":"Mol Genet Metab"},{"key":"3705_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182379","author":"M Arends","year":"2017","unstructured":"Arends M, Biegstraaten M, Hughes DA, Mehta A, Elliott PM, Oder D, et al. Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors. PLoS One. 2017. https:\/\/doi.org\/10.1371\/journal.pone.0182379.","journal-title":"PLoS One."},{"issue":"1","key":"3705_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89(1):44\u201354.","journal-title":"Clin Genet"},{"issue":"4","key":"3705_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jmg-2022-108523","volume":"60","author":"M Gilchrist","year":"2023","unstructured":"Gilchrist M, Casanova F, Tyrrell JS, Cannon S, Wood AR, Fife N, et al. Prevalence of Fabry disease-causing variants in the UK Biobank. J Med Genet. 2023;60(4):391\u20136.","journal-title":"J Med Genet"},{"issue":"6","key":"3705_CR10","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.3390\/ijms24065246","volume":"24","author":"E Cort\u00e9s-Saladelafont","year":"2023","unstructured":"Cort\u00e9s-Saladelafont E, Fern\u00e1ndez-Mart\u00edn J, Ortolano S. Fabry disease and central nervous system involvement: from big to small, from brain to synapse. Int J Mol Sci. 2023;24(6):5246.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3705_CR11","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.jacc.2005.11.070","volume":"47","author":"M Pieroni","year":"2006","unstructured":"Pieroni M, Chimenti C, De Cobelli F, Morgante E, Del Maschio A, Gaudio C, et al. Fabry\u2019s disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol. 2006;47(8):1663\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"3705_CR12","doi-asserted-by":"crossref","unstructured":"Wanner C, Germain DP, Hilz MJ, Spada M, Falissard B, Elliott PM. Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy. Mol Genet Metab [Internet]. 2019 Mar 1 [cited 2024 Feb 9];126(3):210\u20131. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29724657\/","DOI":"10.1016\/j.ymgme.2018.04.004"},{"key":"3705_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0253-6","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015. https:\/\/doi.org\/10.1186\/s13023-015-0253-6.","journal-title":"Orphanet J Rare Dis."},{"key":"3705_CR14","unstructured":"FICHA TECNICA REPLAGAL 1 mg\/ml CONCENTRADO PARA SOLUCION PARA PERFUSION [Internet]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/01189001\/FT_01189001.html"},{"key":"3705_CR15","unstructured":"FICHA TECNICA FABRAZYME 35 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION [Internet]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/01188001\/FT_01188001.html"},{"key":"3705_CR16","unstructured":"FICHA TECNICA ELFABRIO 2 MG\/ML CONCENTRADO PARA SOLUCION PARA PERFUSION [Internet]. [cited 2025 Feb 7]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1231724002\/FT_1231724002.html"},{"key":"3705_CR17","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on Immunogenicity assessment of therapeutic proteins. 2017; Available from: www.ema.europa.eu\/contact"},{"key":"3705_CR18","first-page":"11","volume":"26","author":"S Atiqi","year":"2020","unstructured":"Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-Inhibitors. Front Immunol. 2020;26:11.","journal-title":"Front Immunol"},{"issue":"8","key":"3705_CR19","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/nbt.1484","volume":"26","author":"J Wang","year":"2008","unstructured":"Wang J, Lozier J, Johnson G, Kirshner S, Verthelyi D, Pariser A, et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol. 2008;26(8):901\u20138.","journal-title":"Nat Biotechnol"},{"key":"3705_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107585","author":"A Burlina","year":"2023","unstructured":"Burlina A, Brand E, Hughes D, Kantola I, Kr\u04d3mer J, Nowak A, et al. An expert consensus on the recommendations for the use of biomarkers in Fabry disease. Mol Genet Metab. 2023. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107585.","journal-title":"Mol Genet Metab."},{"issue":"1\u20132","key":"3705_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","volume":"137","author":"DP Germain","year":"2022","unstructured":"Germain DP, Altarescu G, Barriales-Villa R, Mignani R, Pawlaczyk K, Pieruzzi F, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137(1\u20132):49\u201361.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"3705_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","volume":"10","author":"D Bodensteiner","year":"2008","unstructured":"Bodensteiner D, Scott CR, Sims KB, Shepherd GM, Cintron RD, Germain DP. Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme. Genet Med. 2008;10(5):353\u20138.","journal-title":"Genet Med"},{"issue":"21","key":"3705_CR23","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743\u20139.","journal-title":"JAMA"},{"key":"3705_CR24","first-page":"109","volume":"5","author":"K Nicholls","year":"2012","unstructured":"Nicholls K, Bleasel K, Becker G. Severe infusion reactions to fabry enzyme replacement therapy: rechallenge after tracheostomy. JIMD Rep. 2012;5:109.","journal-title":"JIMD Rep"},{"issue":"5","key":"3705_CR25","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1365-2125.2009.03501.x","volume":"68","author":"C Tesmoingt","year":"2009","unstructured":"Tesmoingt C, Lidove O, Reberga A, Thetis M, Ackaert C, Nicaise P, et al. Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies. Br J Clin Pharmacol. 2009;68(5):765\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3705_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","volume":"105","author":"WR Wilcox","year":"2012","unstructured":"Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, et al. Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry. Mol Genet Metab. 2012;105(3):443\u20139.","journal-title":"Mol Genet Metab"},{"issue":"17","key":"3705_CR27","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s40265-021-01621-y","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E. Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in fabry disease. Drugs. 2021;81(17):1969\u201381.","journal-title":"Drugs"},{"issue":"5","key":"3705_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","volume":"55","author":"M Arends","year":"2018","unstructured":"Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018;55(5):351\u20138.","journal-title":"J Med Genet"},{"issue":"6","key":"3705_CR29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs. 2021;81(6):635\u201345.","journal-title":"Drugs"},{"issue":"2","key":"3705_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","volume":"114","author":"T Kizhner","year":"2015","unstructured":"Kizhner T, Azulay Y, Hainrichson M, Tekoah Y, Arvatz G, Shulman A, et al. Characterization of a chemically modified plant cell culture expressed human \u03b1-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015;114(2):259\u201367.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"3705_CR31","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1021\/acs.bioconjchem.8b00133","volume":"29","author":"I Ruderfer","year":"2018","unstructured":"Ruderfer I, Shulman A, Kizhner T, Azulay Y, Nataf Y, Tekoah Y, et al. Development and analytical characterization of pegunigalsidase alfa, a chemically cross-linked plant recombinant human \u03b1-galactosidase-a for treatment of fabry disease. Bioconjug Chem. 2018;29(5):1630\u20139.","journal-title":"Bioconjug Chem"},{"issue":"3","key":"3705_CR32","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jimd.12080","volume":"42","author":"R Schiffmann","year":"2019","unstructured":"Schiffmann R, Goker-Alpan O, Holida M, Giraldo P, Barisoni L, Colvin RB, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year Phase 1\/2 clinical trial. J Inherit Metab Dis. 2019;42(3):534\u201344.","journal-title":"J Inherit Metab Dis"},{"issue":"26","key":"3705_CR33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.omtm.2022.07.009","volume":"8","author":"M Lenders","year":"2022","unstructured":"Lenders M, Pollmann S, Terlinden M, Brand E. Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa. Mol Ther Methods Clin Dev. 2022;8(26):323\u201330.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3705_CR34","first-page":"11","volume":"26","author":"S Atiqi","year":"2020","unstructured":"Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-Inhibitors. Front Immunol. 2020;26:11.","journal-title":"Front Immunol"},{"issue":"6","key":"3705_CR35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ad.2013.02.005","volume":"104","author":"JM Carrascosa","year":"2013","unstructured":"Carrascosa JM. Immunogenicity in biologic therapy: implications for dermatology. Actas Dermosifiliogr. 2013;104(6):471\u20139.","journal-title":"Actas Dermosifiliogr"},{"key":"3705_CR36","first-page":"11","volume":"18","author":"A Vaisman-Mentesh","year":"2020","unstructured":"Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The Molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol. 2020;18:11.","journal-title":"Front Immunol"},{"issue":"2","key":"3705_CR37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","volume":"108","author":"BE Smid","year":"2013","unstructured":"Smid BE, Hoogendijk SL, Wijburg FA, Hollak CEM, Linthorst GE. A revised home treatment algorithm for Fabry disease: influence of antibody formation. Mol Genet Metab. 2013;108(2):132\u20137.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3705_CR38","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in fabry disease. J Am Soc Nephrol. 2016;27(1):256\u201364.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3705_CR39","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66(4):1589\u201395.","journal-title":"Kidney Int"},{"issue":"10","key":"3705_CR40","doi-asserted-by":"publisher","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","volume":"7","author":"SM Rombach","year":"2012","unstructured":"Rombach SM, Aerts JMFG, Poorthuis BJHM, Groener JEM, Donker-Koopman W, Hendriks E, et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One. 2012;7(10):e47805.","journal-title":"PLoS One."},{"key":"3705_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0877-4","author":"W Mauhin","year":"2018","unstructured":"Mauhin W, Lidove O, Amelin D, Lamari F, Caillaud C, Mingozzi F, et al. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. Orphanet J Rare Dis. 2018. https:\/\/doi.org\/10.1186\/s13023-018-0877-4.","journal-title":"Orphanet J Rare Dis."},{"issue":"2","key":"3705_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146(2):77\u201386.","journal-title":"Ann Intern Med"},{"issue":"5","key":"3705_CR43","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18(5):1547\u201357.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3705_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/hrt.2006.104026","volume":"94","author":"DA Hughes","year":"2008","unstructured":"Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94(2):153\u20138.","journal-title":"Heart"},{"key":"3705_CR45","first-page":"25","volume":"1","author":"T Tsukimura","year":"2020","unstructured":"Tsukimura T, Tayama Y, Shiga T, Hirai K, Togawa T, Sakuraba H. Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy. Mol Genet Metab Rep. 2020;1:25.","journal-title":"Mol Genet Metab Rep"},{"issue":"12","key":"3705_CR46","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.1016\/j.gim.2023.100968","volume":"25","author":"D Hughes","year":"2023","unstructured":"Hughes D, Gonzalez D, Maegawa G, Bernat JA, Holida M, Giraldo P, et al. Long-term safety and efficacy of pegunigalsidase alfa: a multicenter 6-year study in adult patients with Fabry disease. Genet Med. 2023;25(12):100968.","journal-title":"Genet Med."},{"issue":"6","key":"3705_CR47","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jmg-2023-109445","volume":"61","author":"EL Wallace","year":"2024","unstructured":"Wallace EL, Goker-Alpan O, Wilcox WR, Holida M, Bernat J, Longo N, et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J Med Genet. 2024;61(6):520\u201330.","journal-title":"J Med Genet"},{"key":"3705_CR48","doi-asserted-by":"crossref","unstructured":"Bernat J, Hughes D, Linhart A, Hopkin RJ, T\u00f8ndel C, Warnock DG, et al. Assessment of immunogenicity from the pegunigalsidase alfa clinical trial program: Integrated analysis of de novo and treatment-boosted anti-drug antibodies. Mol Genet Metab [Internet]. 2024 Feb [cited 2024 Feb 26];141(2):107771. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223004018","DOI":"10.1016\/j.ymgme.2023.107771"},{"issue":"5","key":"3705_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22052680","volume":"22","author":"M Lenders","year":"2021","unstructured":"Lenders M, Scharnetzki D, Heidari A, Di Iorio D, Wegner SV, Brand E. Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease. Int J Mol Sci. 2021;22(5):1\u201313.","journal-title":"Int J Mol Sci"},{"key":"3705_CR50","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00830-5","author":"H Myler","year":"2023","unstructured":"Myler H, Pedras-Vasconcelos J, Lester T, Civoli F, Xu W, Wu B, et al. Neutralizing antibody validation testing and reporting harmonization. AAPS J. 2023. https:\/\/doi.org\/10.1208\/s12248-023-00830-5.","journal-title":"AAPS J."},{"key":"3705_CR51","first-page":"522","volume":"1","author":"L Zhang","year":"2023","unstructured":"Zhang L, Hodsdon ME, Pottanat T, Wang S, Konrad RJ, Seta N, et al. A systematic examination of anti-drug antibody titer estimation: applied recommendations. J Immunol Methods. 2023;1:522.","journal-title":"J Immunol Methods"},{"issue":"5","key":"3705_CR52","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","volume":"48","author":"G Shankar","year":"2008","unstructured":"Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267\u201381.","journal-title":"J Pharm Biomed Anal"},{"key":"3705_CR53","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00649-y","author":"H Myler","year":"2021","unstructured":"Myler H, Pedras-Vasconcelos J, Phillips K, Hottenstein CS, Chamberlain P, Devanaryan V, et al. Anti-drug antibody validation testing and reporting harmonization. AAPS J. 2021. https:\/\/doi.org\/10.1208\/s12248-021-00649-y.","journal-title":"AAPS J."},{"key":"3705_CR54","unstructured":"Immunogenicity Testing of Therapeutic Protein Products \u2014Developing and Validating Assays for Anti-Drug Antibody Detection | FDA [Internet]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug"},{"issue":"2","key":"3705_CR55","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","volume":"126","author":"SJ van der Veen","year":"2019","unstructured":"van der Veen SJ, van Kuilenburg ABP, Hollak CEM, Kaijen PHP, Voorberg J, Langeveld M. Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment. Mol Genet Metab. 2019;126(2):162\u20138.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"3705_CR56","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","volume":"125","author":"CJ Hofbauer","year":"2015","unstructured":"Hofbauer CJ, Whelan SFJ, Hirschler M, Allacher P, Horling FM, Lawo JP, et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood. 2015;125(7):1180\u20138.","journal-title":"Blood"},{"key":"3705_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/antib7020019","author":"KP Pratt","year":"2018","unstructured":"Pratt KP. Anti-drug antibodies: emerging approaches to predict, reduce or reverse biotherapeutic immunogenicity. Antibodies (Basel). 2018. https:\/\/doi.org\/10.3390\/antib7020019.","journal-title":"Antibodies (Basel)."},{"key":"3705_CR58","first-page":"528","volume":"1","author":"JA Weiner","year":"2024","unstructured":"Weiner JA, Natarajan H, McIntosh CJ, Yang ES, Choe M, Papia CL, et al. Selection of positive controls and their impact on anti-drug antibody assay performance. J Immunol Methods. 2024;1:528.","journal-title":"J Immunol Methods"},{"issue":"5","key":"3705_CR59","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.biologicals.2015.06.004","volume":"43","author":"M Wadhwa","year":"2015","unstructured":"Wadhwa M, Knezevic I, Kang HN, Thorpe R. Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility. Biologicals. 2015;43(5):298\u2013306.","journal-title":"Biologicals"},{"issue":"2","key":"3705_CR60","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/jimd.12176","volume":"43","author":"F Stappers","year":"2020","unstructured":"Stappers F, Scharnetzki D, Schmitz B, Manikowski D, Brand SM, Grobe K, et al. Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity. J Inherit Metab Dis. 2020;43(2):334\u201347.","journal-title":"J Inherit Metab Dis"},{"key":"3705_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128351","author":"S Nakano","year":"2015","unstructured":"Nakano S, Tsukimura T, Togawa T, Ohashi T, Kobayashi M, Takayama K, et al. Rapid immunochromatographic detection of serum anti-\u03b1-galactosidase a antibodies in fabry patients after enzyme replacement therapy. PLOS ONE. 2015. https:\/\/doi.org\/10.1371\/journal.pone.0128351.","journal-title":"PLOS ONE"},{"issue":"24","key":"3705_CR62","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.4155\/bio-2018-0287","volume":"10","author":"L Stevenson","year":"2018","unstructured":"Stevenson L, Richards S, Pillutla R, Torri A, Kamerud J, Mehta D, et al. 2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3 - LBA\/cell-based assays: immunogenicity, biomarkers and PK assays). Bioanalysis. 2018;10(24):1973\u20132001.","journal-title":"Bioanalysis"},{"issue":"2","key":"3705_CR63","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jpba.2010.08.029","volume":"54","author":"D Finco","year":"2011","unstructured":"Finco D, Baltrukonis D, Clements-Egan A, Delaria K, Gunn GR, Lowe J, et al. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. J Pharm Biomed Anal. 2011;54(2):351\u20138.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"3705_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2015.02.006","volume":"419","author":"J Hu","year":"2015","unstructured":"Hu J, Wala I, Han H, Nagatani J, Barger T, Civoli F, et al. Comparison of cell-based and non-cell-based assay platforms for the detection of clinically relevant anti-drug neutralizing antibodies for immunogenicity assessment of therapeutic proteins. J Immunol Methods. 2015;419(1):1\u20138.","journal-title":"J Immunol Methods"},{"issue":"6","key":"3705_CR65","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1208\/s12248-016-9954-6","volume":"18","author":"B Wu","year":"2016","unstructured":"Wu B, Chung S, Jiang XR, McNally J, Pedras-Vasconcelos J, Pillutla R, et al. Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. AAPS J. 2016;18(6):1335\u201350.","journal-title":"AAPS J"},{"key":"3705_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1266082","author":"M Lenders","year":"2023","unstructured":"Lenders M, Feidicker LM, Brand SM, Brand E. Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1266082.","journal-title":"Front Immunol."},{"issue":"12","key":"3705_CR67","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neu\u00dfer LP, Rudnicki M, Nordbeck P, Canaan-K\u00fchl S, Nowak A, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with fabry disease. J Am Soc Nephrol. 2018;29(12):2879\u201389.","journal-title":"J Am Soc Nephrol"},{"issue":"16","key":"3705_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21165784","volume":"21","author":"SJ van der Veen","year":"2020","unstructured":"van der Veen SJ, Vlietstra WJ, van Dussen L, van Kuilenburg ABP, Dijkgraaf MGW, Lenders M, et al. Predicting the development of anti-drug antibodies against recombinant alpha-galactosidase a in male patients with classical fabry disease. Int J Mol Sci. 2020;21(16):1\u201314.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3705_CR69","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","volume":"9","author":"PA Van Schouwenburg","year":"2013","unstructured":"Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164\u201372.","journal-title":"Nat Rev Rheumatol"},{"issue":"15","key":"3705_CR70","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/jamainternmed.2013.7430","volume":"173","author":"JR Maneiro","year":"2013","unstructured":"Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med. 2013;173(15):1416\u201328.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"3705_CR71","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/ASN.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Barnd E. Effects of enzyme replacement therapy and antidrug antibodies in patients with fabry disease. J Am Soc Nephrol. 2018;29(9):2265\u201378.","journal-title":"J Am Soc Nephrol"},{"key":"3705_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-017-0152-7","author":"K Tsuboi","year":"2017","unstructured":"Tsuboi K, Yamamoto H. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-na\u00efve Fabry disease patients. BMC Pharmacol Toxicol. 2017. https:\/\/doi.org\/10.1186\/s40360-017-0152-7.","journal-title":"BMC Pharmacol Toxicol."},{"issue":"9","key":"3705_CR73","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/ndt\/gfy357","volume":"34","author":"CV Madsen","year":"2019","unstructured":"Madsen CV, Granqvist H, Petersen JH, Rasmussen \u00c5K, Lund AM, Oturai P, et al. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study. Nephrol Dial Transplant. 2019;34(9):1525\u201333.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"3705_CR74","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ymgme.2019.02.005","volume":"126","author":"H Sasa","year":"2019","unstructured":"Sasa H, Nagao M, Kino K. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan. Mol Genet Metab. 2019;126(4):448\u201359.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3705_CR75","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","volume":"22","author":"H Sakuraba","year":"2018","unstructured":"Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clin Exp Nephrol. 2018;22(4):843\u20139.","journal-title":"Clin Exp Nephrol"},{"issue":"11","key":"3705_CR76","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/jmedgenet-2017-104704","volume":"54","author":"SH Heo","year":"2017","unstructured":"Heo SH, Kang E, Kim YM, Go H, Kim KY, Jung JY, et al. Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy. J Med Genet. 2017;54(11):771\u201380.","journal-title":"J Med Genet"},{"issue":"1","key":"3705_CR77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","volume":"96","author":"B B\u00e9nichou","year":"2009","unstructured":"B\u00e9nichou B, Goyal S, Sung C, Norfleet AM, O\u2019Brien F. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab. 2009;96(1):4\u201312.","journal-title":"Mol Genet Metab"},{"key":"3705_CR78","first-page":"24","volume":"1","author":"K Hongo","year":"2020","unstructured":"Hongo K, Harada T, Fukuro E, Kobayashi M, Ohashi T, Eto Y. Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase A after 6 years of enzyme replacement therapy. Mol Genet Metab Rep. 2020;1:24.","journal-title":"Mol Genet Metab Rep"},{"key":"3705_CR79","first-page":"24","volume":"1","author":"AA Mhanni","year":"2020","unstructured":"Mhanni AA, Auray-Blais C, Boutin M, Johnston A, LeMoine K, Patterson J, et al. Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres. Mol Genet Metab Rep. 2020;1:24.","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"3705_CR80","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/joim.12647","volume":"282","author":"M Lenders","year":"2017","unstructured":"Lenders M, Oder D, Nowak A, Canaan-K\u00fchl S, Arash-Kaps L, Drechsler C, et al. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. J Intern Med. 2017;282(3):241\u201353.","journal-title":"J Intern Med"},{"issue":"7","key":"3705_CR81","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","volume":"77","author":"M Pieroni","year":"2021","unstructured":"Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC, et al. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(7):922\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"3705_CR82","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1080\/17425255.2017.1360280","volume":"13","author":"MS Prado","year":"2017","unstructured":"Prado MS, Bendtzen K, Andrade LEC. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events. Expert Opin Drug Metab Toxicol. 2017;13(9):985\u201395.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"3705_CR83","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345(1):9\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"3705_CR84","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004;75(1):65\u201374.","journal-title":"Am J Hum Genet"},{"key":"3705_CR85","unstructured":"Barbey F, Livio F. Safety of enzyme replacement therapy. Fabry Disease: Perspectives from 5 Years of FOS [Internet]. 2006; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11617\/"},{"issue":"2","key":"3705_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107962","volume":"141","author":"A Mehta","year":"2024","unstructured":"Mehta A, Wallace E, Linhart A, Hughes D, Longo N, T\u00f8ndel C, et al. Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by prior enzyme replacement therapy. Mol Genet Metab. 2024;141(2): 107962.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3705_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107888","volume":"141","author":"D Hughes","year":"2024","unstructured":"Hughes D, Bernat J, Linhart A, Longo N, Mehta A, T\u00f8ndel C, et al. Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by dosing regimens. Mol Genet Metab. 2024;141(2): 107888.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3705_CR88","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","volume":"35","author":"PB Deegan","year":"2012","unstructured":"Deegan PB. Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis. 2012;35(2):227\u201343.","journal-title":"J Inherit Metab Dis"},{"key":"3705_CR89","doi-asserted-by":"crossref","unstructured":"Linthorst GE, Aerts JMFG. Letter concerning \u201cEnzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha\u201d, by Tanaka et al. J Inherit Metab Dis. 2011 Feb;34(1):237.","DOI":"10.1007\/s10545-010-9219-y"},{"issue":"19","key":"3705_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21197213","volume":"21","author":"RP Limgala","year":"2020","unstructured":"Limgala RP, Fikry J, Veligatla V, Goker-Alpan O. The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease. Int J Mol Sci. 2020;21(19):1\u201310.","journal-title":"Int J Mol Sci"},{"key":"3705_CR91","doi-asserted-by":"crossref","unstructured":"Cheung R, Dehart GW, Jesaitis L, Zoog SJ, Melton AC. Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay. J Vis Exp. 2018 Sep 10;2018(139).","DOI":"10.3791\/57777-v"},{"key":"3705_CR92","unstructured":"Moranta FR, Arias FA, Hinojosa J, Mart\u00edn-Arranz MD, Mench\u00e9n L, Mu\u00f1oz F, et al. Monitorizaci\u00f3n terap\u00e9utica de los f\u00e1rmacos biol\u00f3gicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Gastroenterol Hepatol. 2024 Feb 2;"},{"key":"3705_CR93","doi-asserted-by":"crossref","unstructured":"Hunley TE, Corzo D, Dudek M, Kishnani P, Amalfitano A, Chen YT, et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics. 2004 Oct;114(4).","DOI":"10.1542\/peds.2003-0988-L"},{"issue":"4","key":"3705_CR94","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1681\/ASN.2013030290","volume":"25","author":"H Debiec","year":"2014","unstructured":"Debiec H, Valayannopoulos V, Boyer O, N\u00f6el LH, Callard P, Sarda H, et al. Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy. J Am Soc Nephrol. 2014;25(4):675\u201380.","journal-title":"J Am Soc Nephrol"},{"issue":"9981","key":"3705_CR95","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","volume":"385","author":"P Ronco","year":"2015","unstructured":"Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient\u2019s care. Lancet. 2015;385(9981):1983\u201392.","journal-title":"Lancet"},{"issue":"1\u20132","key":"3705_CR96","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ymgme.2020.08.005","volume":"131","author":"D Scharnetzki","year":"2020","unstructured":"Scharnetzki D, Stappers F, Lenders M, Brand E. Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant \u03b1-galactosidase A in patients with Fabry disease. Mol Genet Metab. 2020;131(1\u20132):229\u201334.","journal-title":"Mol Genet Metab"},{"key":"3705_CR97","doi-asserted-by":"crossref","unstructured":"Krishna M, Nadler SG. Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes. Front Immunol. 2016;7(FEB).","DOI":"10.3389\/fimmu.2016.00021"},{"issue":"49","key":"3705_CR98","first-page":"560","volume":"9","author":"H Schellekens","year":"2010","unstructured":"Schellekens H. The immunogenicity of therapeutic proteins. Discov Med. 2010;9(49):560\u20134.","journal-title":"Discov Med"},{"issue":"8","key":"3705_CR99","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/nbt.1484","volume":"26","author":"J Wang","year":"2008","unstructured":"Wang J, Lozier J, Johnson G, Kirshner S, Verthelyi D, Pariser A, et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol. 2008;26(8):901\u20138.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3705_CR100","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13023-024-03049-5","volume":"19","author":"R Mignani","year":"2024","unstructured":"Mignani R, Americo C, Aucella F, Battaglia Y, Cianci V, Sapuppo A, et al. Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study. Orphanet J Rare Dis. 2024;19(1):38.","journal-title":"Orphanet J Rare Dis"},{"key":"3705_CR101","unstructured":"Bernat J, Wallace E, Koulinska I, et al. Impact of PEGylated COVID-19 vaccination on patient tolerability to pegunigalsidase alfa\u2014a new PEGylated enzyme replacement therapy for Fabry disease. SSIEM Congres. 2023. p. B129."},{"issue":"3","key":"3705_CR102","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/cge.14266","volume":"103","author":"E Riccio","year":"2023","unstructured":"Riccio E, Pisani A. New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: switch studies data following agalsidase beta shortage. Clin Genet. 2023;103(3):371\u20136.","journal-title":"Clin Genet"},{"issue":"4","key":"3705_CR103","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/glycob\/cwg034","volume":"13","author":"K Lee","year":"2003","unstructured":"Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology. 2003;13(4):305\u201313.","journal-title":"Glycobiology"},{"key":"3705_CR104","doi-asserted-by":"crossref","unstructured":"Pisani A, Visciano B, Imbriaco M, Di Nuzzi A, Mancini A, Marchetiello C, et al. The kidney in Fabry\u2019s disease. Clin Genet [Internet]. 2014 [cited 2024 Feb 14];86(4):301\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24645664\/","DOI":"10.1111\/cge.12386"},{"issue":"11","key":"3705_CR105","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","volume":"12","author":"O Lidove","year":"2010","unstructured":"Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, et al. Effects of enzyme replacement therapy in Fabry disease\u2013a comprehensive review of the medical literature. Genet Med. 2010;12(11):668\u201379.","journal-title":"Genet Med"},{"issue":"10","key":"3705_CR106","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/gim.2014.28","volume":"16","author":"K Tsuboi","year":"2014","unstructured":"Tsuboi K, Yamamoto H. Clinical course of patients with Fabry disease who were switched from agalsidase-\u03b2 to agalsidase-\u03b1. Genet Med. 2014;16(10):766\u201372.","journal-title":"Genet Med"},{"key":"3705_CR107","unstructured":"European Medicines Agency reviews treatment recommendations for Fabrazyme | European Medicines Agency [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-reviews-treatment-recommendations-fabrazyme"},{"key":"3705_CR108","unstructured":"Assessment report for FABRAZYME agalsidase beta Assessment report on the shortage of Fabrazyme\u2019 Overview of Shortage Period. Available from: www.ema.europa.eu"},{"issue":"1","key":"3705_CR109","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2010.11.155","volume":"102","author":"GE Linthorst","year":"2011","unstructured":"Linthorst GE, Germain DP, Hollak CEM, Hughes D, Rolfs A, Wanner C, et al. Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab. 2011;102(1):99\u2013102.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3705_CR110","first-page":"173","volume":"77","author":"D Ripeau","year":"2017","unstructured":"Ripeau D, Amartino H, Cedrolla M, Urtiaga L, Urdaneta B, Cano M, et al. Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with fabry disease in Latin America. Medicina (BAires). 2017;77(3):173\u20139.","journal-title":"Medicina (BAires)."},{"issue":"3","key":"3705_CR111","first-page":"1683","volume":"11","author":"R Limgala","year":"2019","unstructured":"Limgala R, Jenelle T, Plassmeyer M. Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta\u2014PubMed. Am J Transl Res. 2019;11(3):1683.","journal-title":"Am J Transl Res."},{"key":"3705_CR112","first-page":"95","volume":"25","author":"O Goker-Alpan","year":"2016","unstructured":"Goker-Alpan O, Gambello MJ, Maegawa GHB, Nedd KJ, Gruskin DJ, Blankstein L, et al. Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for fabry disease. JIMD Rep. 2016;25:95\u2013106.","journal-title":"JIMD Rep"},{"issue":"9","key":"3705_CR113","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.2215\/CJN.01820217","volume":"12","author":"R Skrunes","year":"2017","unstructured":"Skrunes R, T\u00f8ndel C, Leh S, Larsen KK, Houge G, Davidsen ES, et al. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease. Clin J Am Soc Nephrol. 2017;12(9):1470\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"3705_CR114","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jcma.2013.11.006","volume":"77","author":"HY Lin","year":"2014","unstructured":"Lin HY, Huang YH, Liao HC, Liu HC, Hsu TR, Shen CI, et al. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa. J Chin Med Assoc. 2014;77(4):190\u20137.","journal-title":"J Chin Med Assoc"},{"issue":"5","key":"3705_CR115","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/jmedgenet-2020-106874","volume":"58","author":"M Lenders","year":"2021","unstructured":"Lenders M, Nordbeck P, Canaan-K\u00fchl S, Kreul L, Duning T, Lorenz L, et al. Treatment switch in Fabry disease\u2014a matter of dose? J Med Genet. 2021;58(5):342\u201350.","journal-title":"J Med Genet"},{"issue":"1","key":"3705_CR116","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1086\/345309","volume":"72","author":"D Blom","year":"2003","unstructured":"Blom D, Speijer D, Linthorst GE, Donker-Koopman WG, Strijland A, Aerts JMFG. Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA. Am J Hum Genet. 2003;72(1):23\u201331.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"3705_CR117","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.ATV.0000209649.60409.38","volume":"26","author":"F Barbey","year":"2006","unstructured":"Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S, et al. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol. 2006;26(4):839\u201344.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"3705_CR118","first-page":"367","volume":"23","author":"\u00d6 Aydin","year":"2013","unstructured":"Aydin \u00d6, Kasapkara \u00c7, \u00c7elik G. Successful Desensitization With Agalsidase Alfa in 2 Brothers With Fabry Disease. J investig allergol clin immunol. 2013;23(5):367\u20138.","journal-title":"J investig allergol clin immunol"},{"issue":"3","key":"3705_CR119","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.iac.2009.04.012","volume":"29","author":"M Castells","year":"2009","unstructured":"Castells M. Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am. 2009;29(3):585\u2013606.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"3705_CR120","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.anai.2020.08.026","volume":"126","author":"I DuBuske","year":"2021","unstructured":"DuBuske I, Schmidlin K, Bernstein JA. Successful desensitization of a patient with Fabry disease with agalsidase beta (Fabrazyme) anaphylaxis after omalizumab pretreatment. Ann Allergy Asthma Immunol. 2021;126(1):96\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3705_CR121","first-page":"13","volume":"9","author":"M Lenders","year":"2022","unstructured":"Lenders M, Brand E. Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease. Front Immunol. 2022;9:13.","journal-title":"Front Immunol"},{"issue":"2","key":"3705_CR122","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.beem.2015.01.006","volume":"29","author":"BW Bigger","year":"2015","unstructured":"Bigger BW, Saif M, Linthorst GE. The role of antibodies in enzyme treatments and therapeutic strategies. Best Pract Res Clin Endocrinol Metab. 2015;29(2):183\u201394.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"3705_CR123","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/21645515.2019.1703453","volume":"16","author":"C Kruiswijk","year":"2020","unstructured":"Kruiswijk C, Richard G, Salverda MLM, Hindocha P, Martin WD, De Groot AS, et al. In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance. Hum Vaccin Immunother. 2020;16(2):277\u201385.","journal-title":"Hum Vaccin Immunother"},{"key":"3705_CR124","doi-asserted-by":"crossref","unstructured":"Hallows WC, Skvorak K, Agard N, Kruse N, Zhang X, Zhu Y, et al. Optimizing human \u03b1-galactosidase for treatment of Fabry disease. Sci Rep. 2023 Dec 1;13(1).","DOI":"10.1038\/s41598-023-31777-4"},{"issue":"6","key":"3705_CR125","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/archderm.143.6.719","volume":"143","author":"S Tyring","year":"2007","unstructured":"Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143(6):719\u201326.","journal-title":"Arch Dermatol"},{"issue":"24","key":"3705_CR126","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.4155\/bio-2017-4974","volume":"9","author":"S Gupta","year":"2017","unstructured":"Gupta S, Richards S, Amaravadi L, Piccoli S, Desilva B, Pillutla R, et al. 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 - LBA: immunogenicity, biomarkers and PK assays). Bioanalysis. 2017;9(24):1967\u201396.","journal-title":"Bioanalysis"},{"issue":"7","key":"3705_CR127","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1248\/bpb.b22-00006","volume":"45","author":"A Yonezawa","year":"2022","unstructured":"Yonezawa A. Therapeutic drug monitoring of antibody drugs. Biol Pharm Bull. 2022;45(7):843\u20136.","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"3705_CR128","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.biologicals.2015.06.004","volume":"43","author":"M Wadhwa","year":"2015","unstructured":"Wadhwa M, Knezevic I, Kang HN, Thorpe R. Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility. Biologicals. 2015;43(5):298\u2013306.","journal-title":"Biologicals"},{"issue":"2","key":"3705_CR129","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.cellimm.2015.03.002","volume":"295","author":"L Yin","year":"2015","unstructured":"Yin L, Chen X, Vicini P, Rup B, Hickling TP. Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. Cell Immunol. 2015;295(2):118\u201326.","journal-title":"Cell Immunol"},{"issue":"4","key":"3705_CR130","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/FTD.0000000000000404","volume":"39","author":"K Bloem","year":"2017","unstructured":"Bloem K, Hern\u00e1ndez-Breijo B, Mart\u00ednez-Feito A, Rispens T. Immunogenicity of therapeutic antibodies: monitoring antidrug antibodies in a clinical context. Ther Drug Monit. 2017;39(4):327\u201332.","journal-title":"Ther Drug Monit"},{"key":"3705_CR131","first-page":"487","volume":"1","author":"A Coddens","year":"2020","unstructured":"Coddens A, Snoeck V, Bontinck L, Buyse MA, Pine SO. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics. J Immunol Methods. 2020;1:487.","journal-title":"J Immunol Methods"},{"key":"3705_CR132","unstructured":"Suh K, Kyei I, Hage DS. Approaches for the detection and analysis of anti-drug antibodies to biopharmaceuticals: a review."},{"key":"3705_CR133","first-page":"1","volume":"22","author":"W Mauhin","year":"2015","unstructured":"Mauhin W, Lidove O, Masat E, Mingozzi F, Mariampillai K, Ziza JM, et al. Innate and adaptive immune response in fabry disease. JIMD Rep. 2015;22:1\u201310.","journal-title":"JIMD Rep"},{"issue":"1","key":"3705_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-018-0916-1","volume":"13","author":"M Lenders","year":"2018","unstructured":"Lenders M, Schmitz B, Brand SM, Brand E. Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact? Orphanet J Rare Dis. 2018;13(1):1\u20132.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3705_CR135","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189\u2013203.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"3705_CR136","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1208\/s12248-016-9954-6","volume":"18","author":"B Wu","year":"2016","unstructured":"Wu B, Chung S, Jiang XR, McNally J, Pedras-Vasconcelos J, Pillutla R, et al. Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. AAPS J. 2016;18(6):1335\u201350.","journal-title":"AAPS J"},{"key":"3705_CR137","doi-asserted-by":"crossref","unstructured":"Silva CAB, Andrade LGM de, Vaisbich MH, Barreto F de C. Brazilian consensus recommendations for the diagnosis, screening, and treatment of individuals with fabry disease: Committee for Rare Diseases - Brazilian Society of Nephrology\/2021. Jornal brasileiro de nefrologia. 2022;44(2):249\u201367.","DOI":"10.1590\/2175-8239-jbn-2021-0208"},{"issue":"2","key":"3705_CR138","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","volume":"117","author":"PS Kishnani","year":"2016","unstructured":"Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab. 2016;117(2):66\u201383.","journal-title":"Mol Genet Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03705-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03705-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03705-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T15:02:39Z","timestamp":1748271759000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03705-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":138,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3705"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03705-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consdent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}